tbuckley/cabot-search huggingface dataset:
Indwelling urinary catheter
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum resistant ovarian cancer (OC).
Authors: Jose Maria Del Campo, Mansoor Raza Mirza, Jonathan S. Berek, Diane M. Provencher, Guenter Emons, Michel Fabbro, Rosemary Lord, Nicoletta Colombo, Edgar Petru, Robert Michael Wenham, Jorn Herrstedt, Lucy Gilbert, Martin Leonhard Heubner, Antonio Gonzalez Martin, Philippe Follana, Benedict B. Benigno, Anne Dørum, Bj Rimel, Sebastien Hazard, Ursula A. Matulonis
Journal: Journal of Clinical Oncology (2017)

5560 Background: Niraparib is a highly selective poly (ADP-ribose) polymerase (PARP) 1/2 inhibitor (PARPi); in preclinical studies, it concentrates in the tumor relative to plasma to deliver durable, near complete PARP inhibition and persistent antitumor effects.Niraparib demonstrated significantly longer progression free survival (PFS) vs placebo in patients (pts) with recurrent OC who were randomized following a complete response (CR) or partial response (PR) to platinum based chemotherapy in the controlled, double-blind phase 3 ENGOT-OV16/NOVA trial. To more fully characterize the NOVA trial population, we assessed platinum resistance status, defined as a duration of response to platinum &lt; 6 months to the most recent (ultimate) platinum regimen. Analysis was limited to pts in the placebo arm, as inclusion of pts receiving active treatment (niraparib) would have confounded the ability to determine duration of response to platinum alone. Methods: Pts with recurrent OC, no prior PARPi use, ≥2 prior courses of platinum based chemotherapy, and CR or PR to the most recent platinum based chemotherapy were eligible. Pts were assigned to one of two cohorts based on g BRCA testing (g BRCAmut or non-g BRCAmut) and randomized 2:1 within each cohort to niraparib 300 mg or placebo qd until progressive disease (PD). Randomization occurred up to 8 weeks following the last dose of the most recent platinum based chemotherapy. PFS was measured from time of randomization to death or earliest PD as assessed by independent review committee. Estimated probability of pts having disease progression in each cohort and pooled across cohorts 6 months after the last dose of their most recent platinum therapy was calculated using the Kaplan-Meier methodology. Results: 181 pts were randomized to placebo (65 g BRCAmut and 116 non-g BRCAmut). Platinum resistance rate estimates for the g BRCAmut, non-g BRCAmut, and pooled cohorts were 42%, 53%, and 49%, respectively. Conclusions: Approximately half of the pts in the NOVA study, where niraparib treatment met its primary endpoint of prolonging PFS following a response to platinum, had developed platinum resistance to their last line of chemotherapy. Clinical trial information: NCT01847274.
Quality of Life and Patient-Reported Outcomes Following Proton Radiation Therapy: A Systematic Review
Authors: Vivek Verma, Charles B Simone, Mark V Mishra
Journal: JNCI Journal of the National Cancer Institute (2017)

As costs of cancer care rise, the importance of documenting value in oncology increases. Proton beam radiotherapy (PBT) has the potential to reduce toxicities in cancer patients, but is relatively expensive and unproven. Evaluating quality of life (QOL) and patient-reported outcomes (PROs) is essential to establishing PBT's "value" in oncologic therapy. The goal of this systematic review was to assess QOL and PROs in patients treated with PBT. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)–guided systematic searches were conducted. The PubMed search engine was the primary data source, along with publications found from references of selected articles, and articles known to the authors published through 2017. Seventeen original investigations were found to have sufficient focus and relevance to be incorporated into the systematic review. Studies of skull base (n = 1), brain (n = 1), head/neck (n = 1), lung (n = 1), breast (n = 2), prostate (n = 8), and pediatric (n = 3) malignancies treated with PBT that met eligibility criteria were included. QOL did not deteriorate during PBT for skull base and after PBT for brain tumors, respectively. PROs were higher for PBT than photon-based radiotherapy for both head/neck and lung cancer. Patient-reported breast cosmesis was appropriate after PBT and comparable to photon modalities. PBT in various settings of prostate cancer displayed an expected post-therapy decline; one study showed improved PROs (rectal urgency, bowel frequency) for PBT, and two others showed PROs/QOL comparable with other modalities. Pediatric studies demonstrated improvements in QOL during therapy, with additional increases thereafter. Based on limited data, PBT provides favorable QOL/PRO profiles for select brain, head/neck, lung, and pediatric cancers; measures for prostate and breast cancers were more modest. These results have implications for cost-effective cancer care and prudently designed QOL evaluation in ongoing trials, which are discussed. Future data could substantially change the conclusions of this review.
DNA methylation of the CYP1A1 and GSTP1 genes and incidence of major cancers (lung, breast and colon) in the PREDIMED-Valencia study
Authors: J.B. Ramirez Sabio, J.V. Sorlí, C. Ortega-Azorín, I. González-Monje, E.M. Asensio, R. Barragán, R. Fernández-Carrión, C. Gallego, R. Estruch, Ó. Coltell, O. Portolés, D. Corella
Journal: Annals of Oncology (2017)
Longer time from diagnosis to docetaxel treatment results in a shorter survival in metastatic hormonosensitive prostate cancer (mHSPC) patients treated with chemotherapy+androgen deprivation therapy (ADT)
Authors: M.A. Climent Duran, B. Mellado, J.M. Piulats Rodriguez, L. Heras Lopez, M.J. Juan, M.I. Sáez, O. Reig, A. Montesa, J.F. Suarez, R. Hajianfar, M.J. Ribal, J. Rubio, M. Castells, R. Villatoro, S. Sandiego, D. Olmos Hidalgo
Journal: Annals of Oncology (2017)
miRNA-loaded exosome-like microparticles as targeted cancer therapy.
Authors: Marianna Proklopi, Aleksandra Filipovic, Costas Pitsillides, Konstantinos Kapnisis, Andreas Anayiotos, Christina Kousparou, Agamemnon A. Epenetos
Journal: Journal of Clinical Oncology (2016)

e14069 Background: Current cancer therapies are partially effective in tumor eradication, due to intrinsic drug resistance as well as failure of therapeutic agents reaching the tumor site. Exosome-like microparticles (MPs) may provide a more efficient way to deliver therapeutics to tumours in a targeted fashion. We have developed improved exosome-like MPs, representing vesicles with relatively uniform size (0.1-1.0 μm), that can be loaded with miRNAs as well as retain their original mesenchymal stem cell (MSC) chemokine profile, allowing them to home into areas of high chemokine expression such as cancer and inflammation. Methods: Exosome-like MPs were released from MSCs of the Wharton's jelly upon cellular stress. Utilizing a state-of-the-art in vitro pharmacokinetics program, with innovative imaging techniques such as in vivoflow cytometry and whole body fluorescence reflectance imaging, we investigated the pharmacokinetic and pharmacodynamic behavior of fluorescently labelled MPs (MP/DiD) containing key anti-cancer miRNAs to define their mode of action and establish safety and efficacy in treating tumors in breast cancer animal models. Results: Exogenously administered MSCs derived exosome-like particles localise within tumor sites where microenvironment resembles inflammation. We used an orthotopic mouse model for breast cancer MDA-MB-231/GFP cells in CD1/nude mice, enabling imaging and assessment of tumor growth in vivo. In vivo flow cytometry of DiD-MPs in tumor-fee mice showed that free, non-internalized MPs were rapidly cleared from circulation, while in vivoimaging demonstrated a reduction in tumor growth over time in mice treated with MPs/DiD compared to untreated mice. Conclusions: Delivery of therapeutic miRNAs via exosome-like MPs affects multiple pathways of cancer development and progression. miRNAs regulate gene expression in cancer cells both through reduction/deletion of oncogenic miRNA and through amplification/overexpression of tumor suppressing miRNA. Thus, compared to earlier approaches targeting single genes, miRNAs delivered in vivo using improved exosome-like particles as vehicles, represent opportunities to target multiple oncogenic molecules in cancer cells offering simultaneously.
DS-1205b, a novel, selective, small-molecule inhibitor of AXL, delays the onset of resistance and overcomes acquired resistance to EGFR-TKIs in a human EGFR-mutant NSCLC (T790M-negative) xenograft model
Authors: T. Jimbo, T. Taira, T. Komatsu, K. Kumazawa, N. Maeda, N. Haginoya, T. Suzuki, M. Ota, Y. Totoki, C. Wada, K. Inaki, T. Isoyama, M. Uno
Journal: Annals of Oncology (2017)
Prognostic stratification of pathologic stage in patients with preoperative chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma
Authors: J. Kang, S.R. Park, Y-H. Kim, H.R. Kim, J.H. Kim, H-Y. Jung, G-H. Lee, H.J. Song, D.H. Kim, K.D. Choi, J-S. Ryu, K-J. Cho, S-B. Kim
Journal: Annals of Oncology (2017)
Association Between Use of Antithrombotic Medication and Hematuria-Related Complications
Authors: Christopher J. D. Wallis, Tristan Juvet, Yuna Lee, Rano Matta, Sender Herschorn, Ronald Kodama, Girish S. Kulkarni, Raj Satkunasivam, William Geerts, Anne McLeod, Steven A. Narod, Robert K. Nam
Journal: JAMA (2017)

<h3>Importance</h3> Antithrombotic medications are among the most commonly prescribed medications. <h3>Objective</h3> To characterize rates of hematuria-related complications among patients taking antithrombotic medications. <h3>Design, Setting, and Participants</h3> Population-based, retrospective cohort study including all citizens in Ontario, Canada, aged 66 years and older between 2002 and 2014. The final follow-up date was December 31, 2014. <h3>Exposures</h3> Receipt of an oral anticoagulant or antiplatelet medication. <h3>Main Outcomes and Measures</h3> Hematuria-related complications, defined as emergency department visit, hospitalization, or a urologic procedure to investigate or manage gross hematuria. <h3>Results</h3> Among 2 518 064 patients, 808 897 (mean [SD] age, 72.1 [6.8] years; 428 531 [53%] women) received at least 1 prescription for an antithrombotic agent over the study period. Over a median follow-up of 7.3 years, the rates of hematuria-related complications were 123.95 events per 1000 person-years among patients actively exposed to antithrombotic agents vs 80.17 events per 1000 person-years among patients not exposed to these drugs (difference, 43.8; 95% CI, 43.0-44.6;<i>P</i> &lt; .001, and incidence rate ratio [IRR], 1.44; 95% CI, 1.42-1.46). The rates of complications among exposed vs unexposed patients (80.17 events/1000 person-years) were 105.78 for urologic procedures (difference, 33.5; 95% CI, 32.8-34.3;<i>P</i> &lt; .001, and IRR, 1.37; 95% CI, 1.36-1.39), 11.12 for hospitalizations (difference, 5.7; 95% CI, 5.5-5.9;<i>P</i> &lt; .001, and IRR, 2.03; 95% CI, 2.00-2.06), and 7.05 for emergency department visits (difference, 4.5; 95% CI, 4.3-4.7;<i>P</i> &lt; .001, and IRR, 2.80; 95% CI, 2.74-2.86). Compared with patients who were unexposed to thrombotic agents, the rates of hematuria-related complications were 191.61 events per 1000 person-years (difference, 117.3; 95% CI, 112.8-121.8) for those exposed to both an anticoagulant and antiplatelet agent (IRR, 10.48; 95% CI, 8.16-13.45), 140.92 (difference, 57.7; 95% CI, 56.9-58.4) for those exposed to anticoagulants (IRR, 1.55; 95% CI, 1.52-1.59), and 110.72 (difference, 26.5; 95% CI, 25.9-27.0) for those exposed to antiplatelet agents (IRR, 1.31; 95% CI, 1.29-1.33). Patients exposed to antithrombotic agents, compared with patients not exposed to these drugs, were more likely to be diagnosed as having bladder cancer within 6 months (0.70% vs 0.38%; odds ratio, 1.85; 95% CI, 1.79-1.92). <h3>Conclusions and Relevance</h3> Among older adults in Ontario, Canada, use of antithrombotic medications, compared with nonuse of these medications, was significantly associated with higher rates of hematuria-related complications (including emergency department visits, hospitalizations, and urologic procedures to manage gross hematuria).
Abstract MP24: Association of Tea Intake with Coronary Artery Calcification and Cardiovascular Events: Results From the Multi-Ethnic Study of Atherosclerosis (MESA)
Authors: P. Elliott Miller, Di Zhao, Erin D Michos, Alexis Frazier-Wood, Michelle Averill, Veit Sandfort, Gregory L Burke, Joseph F Polak, Joao Lima, Wendy S Post, Roger S Blumenthal, Eliseo Guallar, Seth S Martin
Journal: Circulation (2016)

Objective: Tea is one of the most commonly consumed beverages in the world. However, the association of tea intake with coronary artery calcium (CAC) and major adverse cardiovascular events (MACE) remains uncertain. We therefore sought to investigate the association of tea consumption with CAC progression and incident MACE. Methods: From the Multi-Ethnic Study of Atherosclerosis (MESA), we examined 6,212 ethnically-diverse participants with available tea data. Participants were classified as never, &lt;1 cup/day, 1 cup/day, 2-3 cups/day, and ≥4 cups/day. Our main outcomes were CAC progression (measured by cardiac CT), CAC volume progression and MACE [myocardial infarction, angina resulting in revascularization, resuscitated cardiac arrest, stroke, and cardiovascular death]. A CAC progression ratio was derived from mixed effect regression models (visits 1 through 5) using log e (CAC score+1) or log e (CAC volume+1) as the outcome. Cox proportional hazards analyses were used to evaluate the association between tea intake and incident MACE. Results: Over a median follow-up of 11.1 years for CVD events and 5.3 years for cardiac CT follow-up, participants who drank 1 and 2-3 cups/day of tea showed a decreased progression of CAC score and volume compared with never drinkers after multivariate adjustment (Table). This correlated with a statistically significant lower incidence of MACE for 1-cup/day tea drinkers (HR 0.65; 95% CI 0.45, 0.96). Sensitivity analyses excluding Chinese participants showed similar results for CAC progression and incident MACE. Conclusion: We found that being a moderate tea drinker was associated with a decreased progression of CAC and decreased incidence of MACE. Future research is needed to understand the potentially protective nature of moderate tea intake.
FGFR 360° resistance: Establishing a translational research framework in FGFR-altered (FGFRalt) patients (pt) treated with fibroblast growth factor receptor inhibitors (FGFRinh)
Authors: C. Hierro, M. Sánchez-Guixé, F. Ruiz-Pace, J. Jimenez, L. Maynes, A. Azaro, J. Martin-Liberal, M. Ochoa de Olza, I. Braña, M. Vieito, A. Villanueva, H.G. Palmer, J. Arribas, P. Nuciforo, A. Vivancos, E. Garralda, R. Dienstmann, J. Tabernero, V. Serra, J. Rodon
Journal: Annals of Oncology (2017)
Historia de surtos de triquiníase associados ao consumo de carne de cavalo, 1975-1998
Authors: T Ancelle
Journal: Eurosurveillance (1998)

A triquiniase e uma doenca parasitaria transmitida ao homem pelo consumo de carne crua ou mal cozinhada, proveniente de animais contaminados com larvas do genero da Trichinella. Na natureza, o ciclo de vida envolve a maior parte dos carnivoros, omnivoros e numerosos roedores. Os animais domesticos tambem podem ser infestados, em particular os porcos (1).
GW28-e0463 SAFETY OF EARLY LOADING TEST IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION WITH AND WITHOUT Q WAVE
Authors: Raisa Khusainovna Trigulova, Alexander Borisovich Shek, Nadira Akhmatovna Azimova, Nargiza Farkhadovna Tashkenbaeva
Journal: Journal of the American College of Cardiology (2017)
Perioperative versus preoperative chemotherapy with surgery in patients with resectable squamous-cell carcinoma of esophagus: A phase III randomized trial.
Authors: YANG ZHAO, Xin Sui
Journal: Journal of Clinical Oncology (2014)

4037 Background: We assessed whether a regimen of perioperative PCF (paclitaxel, cisplatin, and fluorouracil) to surgery improves outcomes among patients with potentially curable squamous-cell carcinoma of esophagus comparing with preoperative chemotherapy and surgery. Methods: We randomly assigned patients with resectable squamous-cell carcinoma of esophagus to receive either perioperative chemotherapy (175, Arm A) or preoperative chemotherapy (171, Arm B) with surgery.Chemotherapy consisted of two preoperative with or without two postoperative cycles of intravenous paclitaxel (200 mg per square meter of body-surface area) and cisplatin (60 mg per square meter) on day 1, and a continuous intravenous infusion of fluorouracil (700 mg per square meter per day) for 5 days. Primary end point was progression-free survival (PFS), secondary end point was overall survival (OS). Results: PCF-related adverse effects were similar to the previously reported among patients with the squamous-cell carcinoma of esophagus. The postoperative morbidities were similar between the perioperative-chemotherapy-surgery group and the preoperative-chemotherapy-surgery group, as were the numbers of deaths within 30 days after surgery. There were no significant differences in resectability and postoperative pathological stage. With a median follow-up of 50 months of all patients, 104 patients in the perioperative-chemotherapy-surgery group and 114 in the preoperarive-chemotherapy-group had died. As compared with the preoperative-chemotherapy-surgery group, the perioperative-chemotherapy-surgery group had a greater likelihood of progression-free survival (hazard ratio for progression, 0.62; 95 percent confidence interval, 0.49 to 0.73; P < 0.001) and of overall survival (hazard ratio for death, 0.79; 95 percent confidence interval, 0.59 to 0.95; P < 0.001; five-year survival rate, 38 percent vs. 24 percent). Conclusions: In patients with operable esophageal squamous-cell carcinoma, a perioperative regimen of PCF can significantly improved 5-year progression-free and overall survival comparing to preoperative chemotherapy. NCT01225523 Clinical trial information: NCT01225523.
Health-related quality of life after hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer: Results of the phase III OVHIPEC study
Authors: S. Koole, W. van Driel, J. Kieffer, K. Sikorska, J. Schagen van Leeuwen, H. Schreuder, R. Hermans, I. de Hingh, J. van der Velden, H. Arts, L. Massuger, A. Aalbers, V. Verwaal, K. Van de Vijver, N. Aaronson, G. Sonke
Journal: Annals of Oncology (2017)
FGFR1 as a prognostic biomarker and potential therapeutic target in head and neck squamous cell carcinoma.
Authors: Stefan M. Willems, Koos Koole, Diede Brunen, Pauline MD van Kempen, Rob Noorlag, Rhode Bijlsma, Robert J.J. van Es, Cor Lieftink, Remco de Bree, Rene Bernards
Journal: Journal of Clinical Oncology (2016)

6057 Background: FGFR1 (fibroblast growth factor receptor 1) is a promising therapeutic target in multiple types of solid tumors, including head and neck squamous cell carcinoma (HNSCC). FGFR inhibitors have shown great therapeutic value in preclinical models. However, resistance remains a major setback. In this study we have investigated the prognostic value of FGFR1 expression in HNSCC, the therapeutic relevance of targeting FGFR with AZD4547, and potential resistant mechanisms. Methods: Immunohistochemistry and fluorescence in situ hybridization were applied on tissue microarrays to investigate FGFR1 protein expression and FGFR1 gene copy-numbers in 452 HNSCC. The sensitivity of HNSCC cell lines to AZD4547, either as single or combination treatment with gefitinib, was assessed using long-term colony formation assays and biochemical analysis. Results: FGFR1 protein overexpression occurred in 82% (36/44) of HPV-positive HNSCC and 75% (294/392) of HPV-negative HNSCC and relates with poor overall survival and disease-free survival in HPV-negative HNSCC (HR: 2.97; 95% CI: 1.73-6.49; P = 0.001, HR: 1.51; 95% CI: 1.03-2.31; P = 0.036). Moreover, the FGFR1 gene was amplified in 3% (3/110) of HPV-negative oropharyngeal HNSCC. Treatment of the high FGFR1 expressing cell line CCL30 with AZD4547 reduced cell proliferation and FGFR signaling. Two FGFR-amplified cell lines, SCC147 and BICR16, were resistant to AZD4547 treatment due to EGFR signaling. Combined AZD4547 and gefitinib treatment synergistically inhibited proliferation of resistant cell lines. Conclusions: We identify high FGFR1 expression as a candidate prognostic biomarker in HPV-negative HNSCC. Furthermore, we provide a rationale for treating FGFR1-expressing HNSCC with the FGFR inhibitor AZD4547 and FGFR inhibitor-resistant HNSCC with the combination of AZD4547 and gefitinib.
Phase I study of resminostat/S-1 combination in patients with pre-treated biliary tract or pancreatic cancer
Authors: C. Morizane, I. Ohno, H. Ueno, S. Mitsunaga, Y. Hashimoto, T. Okusaka, S. Kondo, M. Sasaki, Y. Sakamoto, H. Takahashi, R. Hara, S. Kobayashi, O. Nakamura, M. Ikeda
Journal: Annals of Oncology (2017)
Circulating osteocrin stimulates bone growth by limiting C-type natriuretic peptide clearance
Authors: Yugo Kanai, Akihiro Yasoda, Keita P. Mori, Haruko Watanabe-Takano, Chiaki Nagai-Okatani, Yui Yamashita, Keisho Hirota, Yohei Ueda, Ichiro Yamauchi, Eri Kondo, Shigeki Yamanaka, Yoriko Sakane, Kazumasa Nakao, Toshihito Fujii, Hideki Yokoi, Naoto Minamino, Masashi Mukoyama, Naoki Mochizuki, Nobuya Inagaki
Journal: Journal of Clinical Investigation (2017)

Although peptides are safe and useful as therapeutics, they are often easily degraded or metabolized. Dampening the clearance system for peptide ligands is a promising strategy for increasing the efficacy of peptide therapies. Natriuretic peptide receptor B (NPR-B) and its naturally occurring ligand, C-type natriuretic peptide (CNP), are potent stimulators of endochondral bone growth, and activating the CNP/NPR-B system is expected to be a powerful strategy for treating impaired skeletal growth. CNP is cleared by natriuretic peptide clearance receptor (NPR-C); therefore, we investigated the effect of reducing the rate of CNP clearance on skeletal growth by limiting the interaction between CNP and NPR-C. Specifically, we generated transgenic mice with increased circulating levels of osteocrin (OSTN) protein, a natural NPR-C ligand without natriuretic activity, and observed a dose-dependent skeletal overgrowth phenotype in these animals. Skeletal overgrowth in OSTN-transgenic mice was diminished in either CNP- or NPR-C-depleted backgrounds, confirming that CNP and NPR-C are indispensable for the bone growth-stimulating effect of OSTN. Interestingly, double-transgenic mice of CNP and OSTN had even higher levels of circulating CNP and additional increases in bone length, as compared with mice with elevated CNP alone. Together, these results support OSTN administration as an adjuvant agent for CNP therapy and provide a potential therapeutic approach for diseases with impaired skeletal growth.